Pancreatic Cancer: A Review of Current Treatment and Novel Therapies

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA A Cancer J Clin. 2019;69(1):1–11. doi:10.3322/caac.21551.
   Web of Science ®Google Scholar
• Howlander N, Noone A, Krapcho M, et al. SEER cancer statistics review, 1975-2017. Bethesda, MD: National Cancer Institute; 2019; Based on November 2019 SEER data submission, posted to the SEER web site April 2020. https://seer.cancer.gov/csr/1975_2017/. Accessed April 1, 2022.
   Google Scholar
• National Cancer Institute. Surveillance, Epidemiology and End Results Program. 2020. https://seer.cancer.gov/explorer/application.html?site=40&data_type=1&graph_type=4&compareBy=sex&chk_sex_1=1&race=1&age_range=1&advopt_precision=1. Accessed December 8, 2020.
   Google Scholar
• Millikan KW, Deziel DJ, Silverstein JC, et al. Prognostic factors associated with resectable adenocarcinoma of the head of the pancreas. Am Surg. 1999;65(7):618–623.
   PubMed Web of Science ®Google Scholar
• Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas - 616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg. 2000;4(6):567–579. doi:10.1016/S1091-255X(00)80105-5.
   PubMed Web of Science ®Google Scholar
• Raut CP, Tseng JF, Sun CC, et al. Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg. 2007;246(1):52–60. doi:10.1097/01.sla.0000259391.84304.2b.
   PubMed Web of Science ®Google Scholar
• Katz MHG, Marsh R, Herman JM, et al. Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design. Ann Surg Oncol. 2013;20(8):2787–2795. doi:10.1245/s10434-013-2886-9.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. Pancreatic Adenocarcinoma, Version 1.2020. www2.tri-kobe/nccn/guideline/pancreas/english/pancreatic.pdf. Published 2019. Accessed May 8 2020.
   Google Scholar
• Schnelldorfer T, Sarr MG. Alessandro codivilla and the first pancreatoduodenectomy. Arch Surg. 2009;144(12):1179–1184. doi:10.1001/archsurg.2009.219.
   PubMedGoogle Scholar
• Whipple AO, Parsons WB, Mullins CR. Treatment of carcinoma of the ampulla of vater. Ann Surg. 1935;102(4):763–779. doi:10.1097/00000658-193510000-00023.
   PubMedGoogle Scholar
• Fernández-del Castillo C, Morales-Oyarvide V, McGrath D, et al. Evolution of the whipple procedure at the Massachusetts general hospital. Surgery. 2012;152(3 Suppl 1):S56–S63. doi:10.1016/j.surg.2012.05.022.
   PubMed Web of Science ®Google Scholar
• Gallitano A, Fransen H, Martin RG. Carcinoma of the pancreas. Results of treatment. Cancer. 1968;22(5):939–944. doi:10.1002/1097-0142(196811)22:5 < 939::aid-cncr2820220507 > 3.0.co;2-e.
   PubMed Web of Science ®Google Scholar
• Winter JM, Cameron JL, Campbell KA, et al. 1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience. J Gastrointest Surg. 2006;10(9):1199–1211. doi:10.1016/j.gassur.2006.08.018.
   PubMed Web of Science ®Google Scholar
• Wright GP, Koehler TJ, Davis AT, Chung MH. The drowning whipple: perioperative fluid balance and outcomes following pancreaticoduodenectomy. J Surg Oncol. 2014;110(4):407–411. doi:10.1002/jso.23662.
   PubMed Web of Science ®Google Scholar
• Hata T, Motoi F, Ishida M, et al. Effect of hospital volume on surgical outcomes after pancreaticoduodenectomy: a systematic review and meta-analysis. Ann Surg. 2016;263(4):664–672. doi:10.1097/SLA.0000000000001437.
   PubMed Web of Science ®Google Scholar
• Macedo FIB, Jayanthi P, Mowzoon M, Yakoub D, Dudeja V, Merchant N. The Impact of surgeon volume on outcomes after pancreaticoduodenectomy: a meta-analysis. J Gastrointest Surg. 2017;21(10):1723–1731. doi:10.1007/s11605-017-3498-7.
   PubMed Web of Science ®Google Scholar
• Bassi C, Dervenis C, Butturini G, et al. Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery. 2005;138(1):8–13. doi:10.1016/j.surg.2005.05.001.
   PubMed Web of Science ®Google Scholar
• Eisenberg JD, Rosato EL, Lavu H, Yeo CJ, Winter JM. Delayed gastric emptying after pancreaticoduodenectomy: an analysis of risk factors and cost. J Gastrointest Surg. 2015;19(9):1572–1580. doi:10.1007/s11605-015-2865-5.
   PubMed Web of Science ®Google Scholar
• Wente MN, Bassi C, Dervenis C, et al. Delayed gastric emptying (DGE) after pancreatic surgery: a suggested definition by the International Study Group of Pancreatic Surgery (ISGPS). Surgery. 2007;142(5):761–768. doi:10.1016/j.surg.2007.05.005.
   PubMed Web of Science ®Google Scholar
• Hanna MM, Gadde R, Allen CJ, et al. Delayed gastric emptying after pancreaticoduodenectomy. J Surg Res. 2016;202(2):380–388. doi:10.1016/j.jss.2015.12.053.
   PubMed Web of Science ®Google Scholar
• Sánchez-Velázquez P, Muller X, Malleo G, et al. Benchmarks in pancreatic surgery: a novel tool for unbiased outcome comparisons. Ann Surg. 2019;270(2):211–218. https://journals.lww.com/annalsofsurgery/Fulltext/2019/08000/Benchmarks_in_Pancreatic_Surgery__A_Novel_Tool_for.4.aspx.
   PubMed Web of Science ®Google Scholar
• Dindo D, Demartines N, Clavien PA. Classification of surgical complications: A new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–213. doi:10.1097/01.sla.0000133083.54934.ae.
   Web of Science ®Google Scholar
• Strobel O, Lorenz P, Hinz U, et al. Actual five-year survival after upfront resection for pancreatic ductal adenocarcinoma: who beats the odds? Ann Surg. 2020;275(5):962–971. https://journals.lww.com/annalsofsurgery/Fulltext/9000/Actual_Five_year_Survival_After_Upfront_Resection.94393.aspx.
   Google Scholar
• Müller SA, Hartel M, Mehrabi A, et al. Vascular resection in pancreatic cancer surgery: survival determinants. J Gastrointest Surg. 2009;13(4):784–792. doi:10.1007/s11605-008-0791-5.
   PubMed Web of Science ®Google Scholar
• Macedo FI, Ryon E, Maithel SK, et al. Survival outcomes associated with clinical and pathological response following neoadjuvant FOLFIRINOX or gemcitabine/nab-paclitaxel chemotherapy in resected pancreatic cancer. Ann Surg. 2019;270(3):400–413. doi:10.1097/SLA.0000000000003468.
   PubMed Web of Science ®Google Scholar
• Katz MHG, Wang H, Fleming JB, et al. Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol. 2009;16(4):836–847. doi:10.1245/s10434-008-0295-2.
   PubMed Web of Science ®Google Scholar
• Kolbeinsson H, Hoppe A, Bayat A, et al. Recurrence patterns and postrecurrence survival after curative intent resection for pancreatic ductal adenocarcinoma. Surgery. 2021;169(3):649–654. doi:10.1016/j.surg.2020.06.042.
   PubMed Web of Science ®Google Scholar
• Groot VP, Rezaee N, Wu W, et al. Patterns, timing, and predictors of recurrence following pancreatectomy for pancreatic ductal adenocarcinoma. Ann Surg. 2018;267(5):936–945. doi:10.1097/SLA.0000000000002234.
   Web of Science ®Google Scholar
• Sperti C, Pasquali C, Piccoli A, Pedrazzoli S. Recurrence after resection for ductal adenocarcinoma of the pancreas. World J Surg. 1997;21(2):195–200. doi:10.1007/s002689900215.
   PubMed Web of Science ®Google Scholar
• Kim RY, Christians KK, Aldakkak M, et al. Total neoadjuvant therapy for operable pancreatic cancer. Ann Surg Oncol. 2021;28(4):2246–2256. doi:10.1245/s10434-020-09149-3.
   PubMed Web of Science ®Google Scholar
• Van Tienhoven G, Versteijne E, Suker M, et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC-1): A randomized, controlled, multicenter phase III trial. JCO. 2018;36(18_suppl):LBA4002–LBA4002. doi:10.1200/JCO.2018.36.18_suppl.LBA4002.
   Web of Science ®Google Scholar
• Janssen QP, van Dam JL, Bonsing BA, et al. Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled t. BMC Cancer. 2021;21(1):300. doi:10.1186/s12885-021-08031-z.
   PubMed Web of Science ®Google Scholar
• Miyasaka Y, Ohtsuka T, Kimura R, et al. Neoadjuvant chemotherapy with gemcitabine plus nab-paclitaxel for borderline resectable pancreatic cancer potentially improves survival and facilitates surgery. Ann Surg Oncol. 2019;26(5):1528–1534. doi:10.1245/s10434-019-07309-8.
   PubMed Web of Science ®Google Scholar
• Gagner M, Pomp A. Laparoscopic pylorus-preserving pancreatoduodenectomy. Surg Endosc. 1994;8(5):408–410. doi:10.1007/BF00642443.
   PubMed Web of Science ®Google Scholar
• Gagner M, Palermo M. Laparoscopic Whipple procedure: review of the literature. J Hepatobiliary Pancreat Surg. 2009;16(6):726–730. doi:10.1007/s00534-009-0142-2.
   PubMedGoogle Scholar
• Croome KP, Farnell MB, Que FG, et al. Pancreaticoduodenectomy with major vascular resection: a comparison of laparoscopic versus open approaches. J Gastrointest Surg. 2015;19(1):189–194; discussion 194. doi:10.1007/s11605-014-2644-8.
   PubMed Web of Science ®Google Scholar
• Kendrick ML, Sclabas GM. Major venous resection during total laparoscopic pancreaticoduodenectomy. HPB (Oxford). 2011;13(7):454–458. doi:10.1111/j.1477-2574.2011.00323.x.
   PubMed Web of Science ®Google Scholar
• Poves I, Burdío F, Morató O, et al. Comparison of perioperative outcomes between laparoscopic and open approach for pancreatoduodenectomy: the PADULAP randomized controlled trial. Ann Surg. 2018;268(5):731–739. doi:10.1097/SLA.0000000000002893.
   PubMed Web of Science ®Google Scholar
• Jiang Y-L, Zhang R-C, Zhou Y-C. Comparison of overall survival and perioperative outcomes of laparoscopic pancreaticoduodenectomy and open pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: a systematic review and meta-analysis. BMC Cancer. 2019;19(1):781. doi:10.1186/s12885-019-6001-x.
   PubMed Web of Science ®Google Scholar
• Yin Z, Jian Z, Hou B, Jin H. Surgical and oncological outcomes of laparoscopic versus open pancreaticoduodenectomy in patients with pancreatic duct adenocarcinoma. Pancreas. 2019;48(7):861–867. doi:10.1097/MPA.0000000000001363.
   PubMed Web of Science ®Google Scholar
• Song KB, Kim SC, Hwang DW, et al. Matched case-control analysis comparing laparoscopic and open pylorus-preserving pancreaticoduodenectomy in patients with periampullary tumors. Ann Surg. 2015;262(1):146–155. doi:10.1097/SLA.0000000000001079.
   PubMed Web of Science ®Google Scholar
• Croome KP, Farnell MB, Que FG, et al. Total laparoscopic pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: oncologic advantages over open approaches? Ann Surg. 2014;260(4):633–640. doi:10.1097/SLA.0000000000000937.
   PubMed Web of Science ®Google Scholar
• Stauffer JA, Coppola A, Villacreses D, et al. Laparoscopic versus open pancreaticoduodenectomy for pancreatic adenocarcinoma: long-term results at a single institution. Surg Endosc. 2017;31(5):2233–2241. doi:10.1007/s00464-016-5222-1.
   PubMed Web of Science ®Google Scholar
• Zureikat AH, Postlewait LM, Liu Y, et al. A multi-institutional comparison of perioperative outcomes of robotic and open pancreaticoduodenectomy. Ann Surg. 2016;264(4):640–649. doi: https://journals.lww.com/annalsofsurgery/Fulltext/2016/10000/A_Multi_institutional_Comparison_of_Perioperative.12.aspx.
   PubMed Web of Science ®Google Scholar
• Adam MA, Choudhury K, Dinan MA, et al. Minimally invasive versus open pancreaticoduodenectomy for cancer: practice patterns and short-term outcomes among 7061 patients. Ann Surg. 2015;262(2):372–377. doi:10.1097/SLA.0000000000001055.
   PubMed Web of Science ®Google Scholar
• Nussbaum DP, Adam MA, Youngwirth LM, et al. Minimally invasive pancreaticoduodenectomy does not improve use or time to initiation of adjuvant chemotherapy for patients with pancreatic adenocarcinoma. Ann Surg Oncol. 2016;23(3):1026–1033. doi:10.1245/s10434-015-4937-x.
   PubMed Web of Science ®Google Scholar
• Bold RJ, Charnsangavej C, Cleary KR, et al. Major vascular resection as part of pancreaticoduodenectomy for cancer: radiologic, intraoperative, and pathologic analysis. J Gastrointest Surg. 1999;3(3):233–243. doi:10.1016/S1091-255X(99)80065-1.
   PubMed Web of Science ®Google Scholar
• Ravikumar R, Sabin C, Abu Hilal M, et al. Portal vein resection in borderline resectable pancreatic cancer: a United Kingdom multicenter study. J Am Coll Surg. 2014;218(3):401–411. doi:10.1016/j.jamcollsurg.2013.11.017.
   PubMed Web of Science ®Google Scholar
• Chua TC, Saxena A. Extended pancreaticoduodenectomy with vascular resection for pancreatic cancer: a systematic review. J Gastrointest Surg. 2010;14(9):1442–1452. doi:10.1007/s11605-009-1129-7.
   PubMed Web of Science ®Google Scholar
• Okada K, Kawai M, Tani M, et al. Surgical strategy for patients with pancreatic body/tail carcinoma: Who should undergo distal pancreatectomy with en-bloc celiac axis resection? Surgery. 2013;153(3):365–372. doi:10.1016/j.surg.2012.07.036.
   PubMed Web of Science ®Google Scholar
• Rubinsky B, Onik G, Mikus P. Irreversible electroporation: a new ablation modality–clinical implications. Technol Cancer Res Treat. 2007;6(1):37–48. doi:10.1177/153303460700600106.
   PubMed Web of Science ®Google Scholar
• Martin RCG, 2nd, McFarland K, Ellis S, Velanovich V. Irreversible electroporation therapy in the management of locally advanced pancreatic adenocarcinoma. J Am Coll Surg. 2012;215(3):361–369. doi:10.1016/j.jamcollsurg.2012.05.021.
   PubMed Web of Science ®Google Scholar
• Maor E, Ivorra A, Leor J, Rubinsky B. The effect of irreversible electroporation on blood vessels. Technol Cancer Res Treat. 2007;6(4):307–312. doi:10.1177/153303460700600407.
   PubMed Web of Science ®Google Scholar
• Ansari D, Kristoffersson S, Andersson R, Bergenfeldt M. The role of irreversible electroporation (IRE) for locally advanced pancreatic cancer: a systematic review of safety and efficacy. Scand J Gastroenterol. 2017;52(11):1165–1171. doi:10.1080/00365521.2017.1346705.
   PubMed Web of Science ®Google Scholar
• Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–1825. doi:10.1056/NEJMoa1011923.
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691–1703. doi:10.1056/NEJMoa1304369.
   PubMed Web of Science ®Google Scholar
• Raphael MJ, Raskin W, Habbous S, et al. The association of drug-funding reimbursement with survival outcomes and use of new systemic therapies among patients with advanced pancreatic cancer. JAMA Netw Open. 2021;4(11):e2133388–e2133388. doi:10.1001/jamanetworkopen.2021.33388.
   PubMed Web of Science ®Google Scholar
• Wang-Gillam A, Li C-P, Bodoky G, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet (London, England. 2016;387(10018):545–557. doi:10.1016/S0140-6736(15)00986-1.
   PubMed Web of Science ®Google Scholar
• Golan T, Hammel P, Reni M, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 2019;381(4):317–327. doi:10.1056/NEJMoa1903387.
   PubMed Web of Science ®Google Scholar
• Carrato A, Vieitez JM, Benavides M, et al. Phase I/II trial of sequential treatment of nab-paclitaxel in combination with gemcitabine followed by modified FOLFOX chemotherapy in patients with untreated metastatic exocrine pancreatic cancer: Phase I results. Eur J Cancer. 2020;139:51–58. doi:10.1016/j.ejca.2020.07.035.
   PubMed Web of Science ®Google Scholar
• Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389(10073):1011–1024. doi:10.1016/S0140-6736(16)32409-6.
   PubMed Web of Science ®Google Scholar
• Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379(25):2395–2406. doi:10.1056/NEJMoa1809775.
   PubMed Web of Science ®Google Scholar
• Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20. doi:10.1056/NEJMoa055531.
   PubMed Web of Science ®Google Scholar
• Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351(17):1731–1740. doi:10.1056/NEJMoa040694.
   PubMed Web of Science ®Google Scholar
• Yamada S, Fujii T, Sugimoto H, et al. Aggressive surgery for borderline resectable pancreatic cancer: evaluation of National Comprehensive Cancer Network guidelines. Pancreas. 2013;42(6):1004–1010. doi:10.1097/MPA.0b013e31827b2d7c.
   PubMed Web of Science ®Google Scholar
• Okada K-I, Hirono S, Kawai M, et al. Phase I study of nab-paclitaxel plus gemcitabine as neoadjuvant therapy for borderline resectable pancreatic cancer. Anticancer Res. 2017;37(2):853–858. doi:10.21873/anticanres.11389.
   PubMed Web of Science ®Google Scholar
• Reni M, Zanon S, Balzano G, et al. A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma. Eur J Cancer. 2018;102:95–102. doi:10.1016/j.ejca.2018.07.007.
   PubMed Web of Science ®Google Scholar
• Murphy JE, Wo JY, Ryan DP, et al. Total neoadjuvant therapy with FOLFIRINOX followed by individualized chemoradiotherapy for borderline resectable pancreatic adenocarcinoma: a phase 2 clinical trial. JAMA Oncol. 2018;4(7):963–969. doi:10.1001/jamaoncol.2018.0329.
   PubMed Web of Science ®Google Scholar
• Ferrone CR, Marchegiani G, Hong TS, et al. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg. 2015;261(1):12–17. doi:10.1097/SLA.0000000000000867.
   PubMed Web of Science ®Google Scholar
• Katz MHG, Shi Q, Ahmad SA, et al. Preoperative modified FOLFIRINOX treatment followed by capecitabine-based chemoradiation for borderline resectable pancreatic cancer: alliance for clinical trials in oncology trial A021101. JAMA Surg. 2016;151(8):e161137. doi:10.1001/jamasurg.2016.1137.
   PubMed Web of Science ®Google Scholar
• Barbour AP, Samra JS, Haghighi KS, et al. The AGITG GAP study: a phase ii study of perioperative gemcitabine and nab-paclitaxel for resectable pancreas cancer. Ann Surg Oncol. 2020;27(7):2506–2515. doi:10.1245/s10434-020-08205-2.
   PubMed Web of Science ®Google Scholar
• OʼReilly EM, Perelshteyn A, Jarnagin WR, et al. A single-arm, nonrandomized phase II trial of neoadjuvant gemcitabine and oxaliplatin in patients with resectable pancreas adenocarcinoma. Ann Surg. 2014;260(1):142–148. doi:10.1097/SLA.0000000000000251.
   PubMed Web of Science ®Google Scholar
• Ielpo B, Duran H, Diaz E, et al. Preoperative treatment with gemcitabine plus nab-paclitaxel is a safe and effective chemotherapy for pancreatic adenocarcinoma. Eur J Surg Oncol. 2016;42(9):1394–1400. doi:10.1016/j.ejso.2016.01.006.
   PubMed Web of Science ®Google Scholar
• MacKenzie S, Zeh H, McCahill LE, PCRT, et al. A pilot phase II multicenter study of nab-paclitaxel (Nab-P) and gemcitabine (G) as preoperative therapy for potentially resectable pancreatic cancer (PC). JCO. 2013;31(15_suppl):4038–4038. doi:10.1200/jco.2013.31.15_suppl.4038.
   PubMed Web of Science ®Google Scholar
• Wei AC, Ou F-S, Shi Q, et al. Perioperative gemcitabine + erlotinib plus pancreaticoduodenectomy for resectable pancreatic adenocarcinoma: ACOSOG Z5041 (alliance) phase II trial. Ann Surg Oncol. 2019;26(13):4489–4497. doi:10.1245/s10434-019-07685-1.
   PubMed Web of Science ®Google Scholar
• Sohal D, Duong MT, Ahmad SA, et al. SWOG S1505: Results of perioperative chemotherapy with mFOLFIRINOX versus gemcitabine/nab-paclitaxel for resectable pancreatic ductal adenocarcinoma. JCO. 2020;38(15_suppl):4504–4504. doi:10.1200/JCO.2020.38.15_suppl.4504.
   Web of Science ®Google Scholar
• Lutfi W, Talamonti MS, Kantor O, et al. Perioperative chemotherapy is associated with a survival advantage in early stage adenocarcinoma of the pancreatic head. Surgery. 2016;160(3):714–724. doi:10.1016/j.surg.2016.05.029.
   PubMed Web of Science ®Google Scholar
• Versteijne E, Vogel JA, Besselink MG, et al. Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer. Br J Surg. 2018;105(8):946–958. doi:10.1002/bjs.10870.
   PubMed Web of Science ®Google Scholar
• Kalser MH, Ellenberg SS. Pancreatic cancer: adjuvant combined radiation and chemotherapy following curative resection. Arch Surg. 1985;120(8):899–903. doi:10.1001/archsurg.1985.01390320023003.
   PubMed Web of Science ®Google Scholar
• Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg. 1999;230(6):776–776. doi:10.1097/00000658-199912000-00006.
   PubMed Web of Science ®Google Scholar
• Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350(12):1200–1210. doi:10.1056/NEJMoa032295.
   PubMed Web of Science ®Google Scholar
• Smeenk HG, van Eijck CHJ, Hop WC, et al. Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation: long-term results of EORTC trial 40891. Ann Surg. 2007;246(5):734–740. doi:10.1097/SLA.0b013e318156eef3.
   PubMed Web of Science ®Google Scholar
• Van Laethem J-L, Hammel P, Mornex F, et al. Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study. JCO. 2010;28(29):4450–4456. doi:10.1200/JCO.2010.30.3446.
   PubMed Web of Science ®Google Scholar
• Palta M, Godfrey D, Goodman KA, et al. Radiation therapy for pancreatic cancer: executive summary of an ASTRO clinical practice guideline. Pract Radiat Oncol. 2019;9(5):322–332. doi:10.1016/j.prro.2019.06.016.
   PubMed Web of Science ®Google Scholar
• Kim EJ, Ben-Josef E, Herman JM, et al. A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer. Cancer. 2013;119(15):2692–2700. doi:10.1002/cncr.28117.
   PubMed Web of Science ®Google Scholar
• Shroff RT, Varadhachary GR, Crane CH, et al. Updated survival analysis of preoperative gemcitabine (gem) plus bevacizumab (bev)-based chemoradiation for resectable pancreatic adenocarcinoma. JCO. 2012;30(15_suppl):4051–4051. doi:10.1200/jco.2012.30.15_suppl.4051.
   PubMedGoogle Scholar
• Evans DB, Varadhachary GR, Crane CH, et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. JCO. 2008;26(21):3496–3502. doi:10.1200/JCO.2007.15.8634.
   PubMed Web of Science ®Google Scholar
• Talamonti MS, Small W, Mulcahy MF, et al. A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Ann Surg Oncol. 2006;13(2):150–158. doi:10.1245/ASO.2006.03.039.
   PubMed Web of Science ®Google Scholar
• Epelbaum R, Rosenblatt E, Nasrallah S, et al. Phase II study of gemcitabine combined with radiation therapy in patients with localized, unresectable pancreatic cancer. J Surg Oncol. 2002;81(3):138–143. doi:10.1002/jso.10159.
   PubMed Web of Science ®Google Scholar
• Joensuu TK, Kiviluoto T, Kärkkäinen P, et al. Phase I-II trial of twice-weekly gemcitabine and concomitant irradiation in patients undergoing pancreaticoduodenectomy with extended lymphadenectomy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2004;60(2):444–452. doi:10.1016/j.ijrobp.2004.03.026.
   PubMed Web of Science ®Google Scholar
• Small WJ, Berlin J, Freedman GM, et al. Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial. J Clin Oncol. 2008;26(6):942–947. doi:10.1200/JCO.2007.13.9014.
   PubMed Web of Science ®Google Scholar
• Stessin AM, Meyer JE, Sherr DL. Neoadjuvant radiation is associated with improved survival in patients with resectable pancreatic cancer: an analysis of data from the surveillance, epidemiology, and end results (SEER) registry. Int J Radiat Oncol Biol Phys. 2008;72(4):1128–1133. doi:10.1016/j.ijrobp.2008.02.065.
   PubMed Web of Science ®Google Scholar
• Effenberger KE, Schroeder C, Hanssen A, et al. Improved risk stratification by circulating tumor cell counts in pancreatic cancer. Clin Cancer Res. 2018;24(12):2844–2850. doi:10.1158/1078-0432.CCR-18-0120.
   PubMed Web of Science ®Google Scholar
• Court CM, Ankeny JS, Sho S, et al. Circulating tumor cells predict occult metastatic disease and prognosis in pancreatic cancer. Ann Surg Oncol. 2018;25(4):1000–1008. doi:10.1245/s10434-017-6290-8.
   PubMed Web of Science ®Google Scholar
• Sivapalan L, Kocher HM, Ross-Adams H, Chelala C. Molecular profiling of ctDNA in pancreatic cancer: opportunities and challenges for clinical application. Pancreatology. 2021;21(2):363–378. doi:10.1016/j.pan.2020.12.017.
   PubMed Web of Science ®Google Scholar
• Botta GP, Abdelrahim M, Aushev VN, et al. Association of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinoma. JCO. 2022;40(4_suppl):517–517. doi:10.1200/JCO.2022.40.4_suppl.517.
   PubMed Web of Science ®Google Scholar
• Hackert T, Niesen W, Hinz U, et al. Radical surgery of oligometastatic pancreatic cancer. Eur J Surg Oncol. 2017;43(2):358–363. 10.1016/j.ejso.2016.10.023.
   PubMed Web of Science ®Google Scholar
• Adam R, Chiche L, Aloia T, et al. Hepatic resection for noncolorectal nonendocrine liver metastases: analysis of 1,452 patients and development of a prognostic model. Ann Surg. 2006;244(4):524–535. doi:10.1097/01.sla.0000239036.46827.5f.
   PubMed Web of Science ®Google Scholar
• Shrikhande SV, Kleeff J, Reiser C, et al. Pancreatic Resection for M1 Pancreatic Ductal Adenocarcinoma. Ann Surg Oncol. 2007;14(1):118–127. doi:10.1245/s10434-006-9131-8.
   PubMed Web of Science ®Google Scholar
• Gleisner AL, Assumpcao L, Cameron JL, et al. Is resection of periampullary or pancreatic adenocarcinoma with synchronous hepatic metastasis justified? Cancer. 2007;110(11):2484–2492. doi:10.1002/cncr.23074.
   PubMed Web of Science ®Google Scholar
• Ilmer M, Schiergens TS, Renz BW, et al. Oligometastatic pulmonary metastasis in pancreatic cancer patients: Safety and outcome of resection. Surg Oncol. 2019;31:16–21. 10.1016/j.suronc.2019.08.010.
   PubMed Web of Science ®Google Scholar
• Yamashita K, Miyamoto A, Hama N, et al. Survival impact of pulmonary metastasis as recurrence of pancreatic ductal adenocarcinoma. Dig Surg. 2015;32(6):464–471. doi:10.1159/000439545.
   PubMed Web of Science ®Google Scholar
• Ensminger WD. Intrahepatic arterial infusion of chemotherapy: pharmacologic principles. Semin Oncol. 2002;29(2):119–125. doi:10.1053/sonc.2002.31679.
   PubMed Web of Science ®Google Scholar
• Groot Koerkamp B, Sadot E, Kemeny NE, et al. Perioperative hepatic arterial infusion pump chemotherapy is associated with longer survival after resection of colorectal liver metastases: a propensity score analysis. JCO. 2017;35(17):1938–1944. doi:10.1200/JCO.2016.71.8346.
   PubMed Web of Science ®Google Scholar
• Beger HG, Gansauge F, Büchler MW, Link KH. Intraarterial adjuvant chemotherapy after pancreaticoduodenectomy for pancreatic cancer: Significant reduction in occurrence of liver metastasis. In. World Journal of Surgery. 1999;23(9):946–949. doi:10.1007/s002689900604.
   PubMed Web of Science ®Google Scholar
• Ohigashi H, Ishikawa O, Eguchi H, et al. Feasibility and efficacy of combination therapy with preoperative and postoperative chemoradiation, extended pancreatectomy, and postoperative liver perfusion chemotherapy for locally advanced cancers of the pancreatic head. Ann Surg Oncol. 2005;12(8):629–636. doi:10.1245/ASO.2005.05.028.
   PubMed Web of Science ®Google Scholar
• Wang Y, Xu Y, Zheng Y, Bao Y, Wang P. Postoperative hepatic arterial infusion chemotherapy improved survival of pancreatic cancer after radical pancreatectomy: a retrospective study. Onco Targets Ther. 2018;11:903–907. doi:10.2147/OTT.S153886.
   PubMed Web of Science ®Google Scholar
• Tajima H, Kitagawa H, Tsukada T, et al. Hepatic arterial infusion chemotherapy with gemcitabine and 5-fluorouracil or oral S-1 improves the prognosis of patients with postoperative liver metastases from pancreatic cancer. Mol Clin Oncol. 2013;1(5):869–874. doi:10.3892/mco.2013.152.
   PubMedGoogle Scholar
• Sohal DPS, Kennedy EB, Cinar P, et al. Metastatic pancreatic cancer: ASCO guideline update. JCO. 2020;38(27):3217–3230. doi:10.1200/JCO.20.01364.
   PubMed Web of Science ®Google Scholar
• Casolino R, Paiella S, Azzolina D, et al. Homologous recombination deficiency in pancreatic cancer: a systematic review and prevalence meta-analysis. J Clin Oncol. 2021;39(23):2617–2631. doi:10.1200/JCO.20.03238.
   PubMed Web of Science ®Google Scholar
• Dalmasso B, Puccini A, Catalano F, et al. Beyond BRCA: the emerging significance of DNA damage response and personalized treatment in pancreatic and prostate cancer patients. IJMS. 2022;23(9):4709. doi:10.3390/ijms23094709.
   Google Scholar
• Registry. APG. Pancreatic Cancer Genomic Distribution: Mutated Genes. https://www.aacr.org/professionals/research/aacr-project-genie/aacr-project-genie-data/11-most-common-cancer-types-in-the-aacr-project-genie-registry/pancreatic-cancer/. Published 2022.
   Google Scholar
• Strickler JH, Satake H, Hollebecque A, et al. First data for sotorasib in patients with pancreatic cancer with KRAS p.G12C mutation: A phase I/II study evaluating efficacy and safety. JCO. 2022;40(36_suppl):360490–360490. doi:10.1200/JCO.2022.40.36_suppl.360490.
   Web of Science ®Google Scholar
• Bekaii-Saab TS, Spira AI, Yaeger R, et al. KRYSTAL-1: Updated activity and safety of adagrasib (MRTX849) in patients (Pts) with unresectable or metastatic pancreatic cancer (PDAC) and other gastrointestinal (GI) tumors harboring a KRASG12C mutation. JCO. 2022;40(4_suppl):519–519. doi:10.1200/JCO.2022.40.4_suppl.519.
   PubMed Web of Science ®Google Scholar
• Golan T, Khvalevsky EZ, Hubert A, et al. RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients. Oncotarget. 2015;6(27):24560–24570. doi:10.18632/oncotarget.4183.
   PubMedGoogle Scholar
• Leidner R, Sanjuan Silva N, Huang H, et al. Neoantigen T-cell receptor gene therapy in pancreatic cancer. N Engl J Med. 2022;386(22):2112–2119. doi:10.1056/NEJMoa2119662.
   PubMed Web of Science ®Google Scholar
• Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the Phase II KEYNOTE-158 study. J Clin Oncol. 2020;38(1):1–10. doi:10.1200/JCO.19.02105.
   PubMed Web of Science ®Google Scholar
• Chellakkan SB, Dinesh C, Wilber Q-T, et al. Listeria delivers tetanus toxoid protein to pancreatic tumors and induces cancer cell death in mice. Sci Transl Med. 2022;14(637):eabc1600. doi:10.1126/scitranslmed.abc1600.
   PubMed Web of Science ®Google Scholar
• Pishvaian MJ, Garrido-Laguna I, Liu SV, Multani PS, Chow-Maneval E, Rolfo C. Entrectinib in TRK and ROS1 fusion-positive metastatic pancreatic cancer. JCO Precis Oncol. 2018;(2):1–7. doi:10.1200/PO.18.00039.
   PubMed Web of Science ®Google Scholar